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Breast cancer is the most common malignancy affecting women worldwide. While a small fraction of breast 
cancers have a hereditary component, environmental and behavioral factors also impact the development of 
cancer. Human cytomegalovirus (HCMV) is a member of the Herpesviridae family that is widespread in the 
general population and has been linked to several forms of cancer. While HCMV DNA has been found in some 
breast cancer tissue specimens, we wanted to investigate whether a secreted viral cytokine might have an effect 
on cancerous or even pre-cancerous cells. HCMV encodes an ortholog of the human cellular cytokine 
interleukin-10 (IL-10). The HCMV UL111A gene product is cmvIL-10, which has 27% sequence identity to 
IL-10 and binds the cellular IL-10 receptor (IL-10R) to induce downstream cell signaling. We found that MCF-7 
human breast cancer cells express IL-10R and that exposure to cmvIL-10 results in enhanced proliferation and 
increased chemotaxis of MCF-7 cells. PCR arrays revealed that treatment with cmvIL-10 alters expression of 
cell adhesion molecules and increases MMP gene expression. In particular, MMP-10 gene expression was found 
to be significantly up-regulated and this correlated with an increase in cell-associated MMP-10 protein produced 
by MCF-7 cells exposed to cmvIL-10. These results suggest that the presence of cmvIL-10 in the tumor 
microenvironment could contribute to the development of more invasive tumors. 
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Introduction 
Breast cancer is a significant cause of cancer deaths for 
women in the United States. While there are many known 
risk factors for breast cancer, infectious disease has recently 
emerged as one likely contributor to carcinogenesis [1]. 
Human cytomegalovirus (HCMV) is a widespread pathogen 
in the general population, and it may cause acute, persistent, 
or lifelong latent infection [2]. Seroprevalence of HCMV 
infection in the United States ranges from 50-90% for middle 
aged adults [3, 4] and correlates directly to exchange of bodily 
fluids [5]. Factors elevating HCMV incidence between 
populations include poor socioeconomic conditions and 
high-risk sexual practices [6, 7]. HCMV typically causes 
clinical disease only in immune-compromised individuals, 
but recent evidence has demonstrated strong links between 
HCMV and breast cancer [8, 9].  
Although HCMV DNA and proteins have been detected in 
breast cancer tissue samples [8, 9], there is no evidence that 
infection is an initiating factor in tumor development. 
HCMV is not considered a transforming virus but has instead 
been described as oncomodulatory because of the presence of 
HCMV in several types of tumors [10]. The virus harbors 
numerous mechanisms for influencing tumor progression, 
such as immediate early proteins IE1 and IE2, which impact 
cell cycle progression and stimulate cellular DNA replication 
[11], and the action of the UL97 protein kinase, which 
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inactivates tumor suppressor Rb via phosphorylation [12]. In 
addition, neuroblastoma cells infected with HCMV were 
found to have decreased expression of NCAM/CD56 (neural 
cell adhesion molecule) and enhanced penetration of 
endothelial cell layers [13]. HCMV infection of prostate 
cancer and glioma cells was shown to result in promote 
activation of focal adhesion kinase (FAK) and augment 
attachment to and migration along the extracellular matrix 
(ECM) [14, 15].  
Successful evasion of normal immune clearance 
mechanisms is another property of cancer cells, and HCMV 
has a variety of strategies for modulation of the host immune 
system [16]. The US2, US3, US6 and US11 gene products of 
HCMV coordinate to decrease major histocompatibility 
complex (MHC) class I presentation at the cell surface [17, 18], 
impairing the ability of cytotoxic T lymphocytes (CTLs) to 
recognize and lyse infected cells. In addition, a viral ortholog 
of human cellular interleukin-10 encoded by UL111A 
(known as cmvIL-10) was found to inhibit inflammatory 
cytokine secretion [19, 20]. While most viral genes are 
expressed in the infected cell, cmvIL-10 is secreted from the 
infected cell and has the potential to enter the bloodstream 
and act on any cell, infected or not, that expresses the IL-10 
receptor. Indeed, cmvIL-10 was also found to play a pivotal 
role in the progression of malignant glioma by enhancing the 
invasiveness and migration of glioma cancer stem cells [21].  
We have previously shown that the triple negative breast 
cancer cell line MDA-MB-321 expresses the IL-10R and that 
enhanced cell proliferation and migration occurs when these 
cells are exposed to cmvIL-10, potentially increasing the 
likelihood of metastasis formation [22]. Here, we show that 
cmvIL-10 can induce the same effects on the estrogen 
receptor (ER)-positive MCF-7 breast cancer cell line, 
suggesting that the viral cytokine has the potential to impact 
a variety of tumor types in vivo.  
Materials and Methods 
Cells and Reagents. MCF-7 (American Type Culture 
Collection, ATCC, Manassas, VA), an ER-positive invasive 
ductal carcinoma breast cell line, was grown at 37°C in a 
humidified 5% carbon dioxide incubator in Dulbecco’s 
Modified Eagle Medium Nutrient Mixture F12 (DMEM/F12, 
GIBCO, Grand Island, NY) supplemented with 10% Fetal 
Bovine Serum (FBS, Sigma-Aldrich, St. Louis, MO).     
Recombinant cmvIL-10 was purchased from R&D Systems 
(Minneapolis, MN). 
Flow Cytometry. MCF-7 cells were grown to 80% 
confluence in T75 flasks and serum starved for 24 hours 
prior to harvesting.  Cells were scraped into serum-free 
media, pelleted, and resuspended in FACS buffer (PBS pH 
7.4, 0.5% BSA, 0.02% sodium azide). Samples of 1x105 cells 
each were stained with 5 μL anti-IL-10Rα-PE (R&D 
Systems, FAB6280P) or anti-IL-10Rβ-PE (R&D Systems, 
FAB874P) in a total volume of 100 μL FACS buffer on ice 
in the dark for 60 minutes. The antibodies used as isotype 
controls were, respectively, goat IgG-PE (R&D Systems, 
IC108P) and mouse IgG1-PE (R&D Systems, 554680). The 
cells were washed three times and fixed in 100 μL cold 
FACS buffer plus 100 μL PBS containing 2% 
paraformaldehyde.  Each sample was analyzed using a 
Becton-Dickinson FACSCalibur with Cell Quest Pro 
software. 
Immunofluorescence Microscopy. MCF-7 cells were 
seeded on FBS-treated glass coverslips in 6-well plates at 
2x105 cells per well. The cells were allowed to adhere and 
grow for 48 hours to achieve 80% confluence. The media 
was removed and replaced with serum free media overnight. 
The cells were washed with PBS, fixed in 4% 
paraformaldehyde, then permeabilized with 0.2% 
Triton-X-100 in phosphate-buffered saline (PBS) for 15 
minutes, followed by an ice-cold acetone:methanol solution 
for 30 minutes at room temperature.  The cells were blocked 
with 10% FBS in PBS at 37°C for 1 hour, then stained with 
anti-IL-10Rα (Santa Cruz Biotechnology, Santa Cruz, CA, 
sc-98) for 1 hour, followed by goat anti-rabbit-TRITC 
(Southern Biotech, Birmingham, AL, #4010-03) for 30 
minutes in the dark. Antibodies were diluted with antibody 
dilution buffer (1% BSA, 0.5% Tween-20, 1X PBS) 
according to the manufacturer’s instructions. All cover slips 
were mounted in ProLong Gold anti-fade reagent with DAPI 
(Invitrogen, Carlsbad, CA) and analyzed with an inverted 
AxioObserver fluorescence microscope (Carl Zeiss 
Microscopy, Oberkochen, Germany) mounted with a digital 
camera.  Digital images were taken with AxioVision Rel 
4.8 software (Carl Zeiss Microscopy). 
Cell Proliferation Assay. MCF-7 cells were seeded into 96 
well dishes at a density of 1x104 cells per well in complete 
medium with varying doses of cmvIL-10.  The rate of DNA 
synthesis was measured at the indicated time points using the 
BrdU Cell Proliferation ELISA kit (Roche, Basel, 
Switzerland) according to manufacturer’s instructions.   
Total luminescence was determined using Promega Glomax 
Luminometer and Glomax software. 
Migration Assays. MCF-7 cells were cultivated in T75 
flasks to 80% confluence, then incubated in serum-free 
media in the presence or absence of 100 ng/mL cmvIL-10 for 
24 hours.  Cells were harvested via scraping, washed, and 
resuspended in fresh serum free media. Trans-well migration 
was assayed using 8 um pore size filter inserts (ThinCerts, 
Greiner Bio One, Monroe, North Carolina) that were loaded 
into 24-well plates using sterile tweezers to create two 
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separate chambers. A total of 2x105 cells in a volume of 100 
μL were dispensed into each upper chamber. Lower 
chambers were loaded with 600 μL media with the indicated 
dose of FBS. For cells that had been pre-incubated with 
cmvIL-10, both the upper and lower chambers contained 100 
ng/ml cmvIL-10 during the assay. The plates were incubated 
at 37°C for 4 hours, and then cells were harvested from the 
lower chamber by dipping the filter in the lower chamber 
media 10 times and rinsing the bottom of the filter twice 
using lower chamber media. Media and cells that were 
adhered to the outside of the filter were removed by pipet, 
and then the medium from the lower chamber well was 
collected, transferred to a microfuge tube, and centrifuged at 
1000 rpm for 5 minutes. The supernatant was removed, 
pellets resuspended in 100 µL of media, then placed into a 
white clear bottom assay plate. Cell number was quantified 
via luminometry using the Cell Titre Glo Assay (Promega, 
Madison, WI) according to the manufacturer’s instructions.  
Figure 1. MCF-7 cells 
express IL-10R and 
respond to cmvIL-10. 
A) MCF-7 cells were 
stained with PE- 
conjugated antibodies 
directed against IL- 10R 
(red lines) or 
appropriate isotype 
control (blue lines) and 
analyzed by flow 
cytometry. B) MCF-7 
cells were grown on 
glass coverslips, fixed, 
permeabilized, and 
stained for IL-10Rα 
followed by TRITC 
conjugated secondary 
antibody. Coverslips 
were mounted with 
Prolong Gold containing 
DAPI (blue).  C) MCF-7 
cells were grown in 
96-well dishes and 
treated with the 
indicated doses of 
cmvIL-10 then analyzed 
using the BrdU Cell 
Proliferation ELISA. D) 
Cell migration was 
evaluated in a modified 
Boyden chamber assay. 
Cells crossing the 8 um 
filter into the lower 
chamber after four 
hours were quantified 
using the Cell Titre Glo 
Assay. Error bars 
represent standard 
error. * indicates p < 
0.01, Student’s t test. 
These results are 
representative of three 
independent 
experiments. 
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Table 1. Tumor Metastasis Array1 Gene Expression Analysis 
Unigene Refseq Symbol Description Fold Change2 p value 
Hs.158932 NM_000038 MCAM Melanoma cell adhesion molecule 8.13 0.0054 
Hs.2258 NM_002425 MMP10 Matrix metalloproteinase 10 (stromelysin 2) 4.86 0.0182 
Hs.297413 NM_004994 MMP9 Matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 
92kDa type IV collagenase) 
2.41 0.0512 
Hs.333418 NM_014164 FXYD5 FXYD domain containing ion transport regulator 5 2.24 0.0011 
Hs.2256 NM_002423 MMP7 Matrix metalloproteinase 7 (matrilysin, uterine) 1.64 0.0074 
Hs.513617 NM_004530 MMP2 Matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 
72kDa type IV collagenase) 
1.47 0.0494 
Hs.143751 NM_005940 MMP11 Matrix metalloproteinase 11 (stromelysin 3) 1.45 0.0037 
Hs.2936 NM_002427 MMP13 Matrix metalloproteinase 13 (collagenase 3) 1.39 0.0404 
Hs.375129 NM_002422 MMP3 Matrix metalloproteinase 3 (stromelysin 1, progelatinase) 1.32 0.0097 
Hs.633514 NM_003255 TIMP2 TIMP metalloproteinase inhibitor 2 1.21 0.0088 
Hs.644633 NM_000362 TIMP3 TIMP metalloproteinase inhibitor 3 1.18 0.0043 
Hs.591665 NM_003256 TIMP4 TIMP metalloproteinase inhibitor 4 1.09 0.0326 
Hs.158932 NM_000038 APC Adenomatous polyposis coli 0.71 0.0001 
Hs.371720 NM_003177 SYK Spleen tyrosine kinase 0.68 0.0054 
Hs.461086 NM_004360 CDH1 Cadherin 1, type 1, E-cadherin (epithelial) 0.56 0.0048 
1 The complete list of genes analyzed using the Human Tumor Metastasis RT2 Profiler PCR Array (SABiosciences, Valencia, 
CA) includes: APC, BRMS1, CCL7, CD44, CD82, CDH1, CDH11, CDH6, CDKN2A, CHD4, COL4A2, CST7, CTBP1, CTNNA1, 
CTSK, CTSL1, CXCL12, CXCR2, CXCR4, DENR, EPHB2, ETV4, EWSR1, FAT1, FGFR4, FLT4, FN1, FXYD5, GNRH1, KISS1, 
KISS1R, KRAS, HGF, HPSE, HRAS, HTATIP2, IGF1, IL18, IL1B,  ITGA7, ITGB3, MCAM, MDM2, MET, METAP2, MGAT5, 
MMP10, MMP11, MMP13, MMP2, MMP3, MMP7, MMP9, MTA1, MTSS1, MYC, MYCL1, NF2, NME1, NME2, NME4, NR4A3, 
PLAUR, PNN, PTEN, RB1, RORB, RPSA, SET, SMAD2, SMAD4, SRC, SSTR2, SYK, TCF20, TGFB1, TIMP2, TIMP3, TIMP4, 
TNFSF10, TP53, TRPM1, TSHR, VEGFA, B2M, HPRT1, RPL13A, GAPDH, ACTB. 2 Fold change was calculated by comparison 
of ΔΔCt values for cmvIL-10 treated cells compared to untreated cells for three biological replicates.  Statistical analysis was 
performed by Student’s t test. For genes not listed in the table, the fold change was between 0.8 and 1.5, the p value was >0.05, 
or both. 
qPCR Arrays. Two T75 flasks at 90% confluence 
containing 3x106 MCF-7 cells each were treated with 100 
ng/mL purified recombinant cmvIL-10 (R&D Systems) for 
24 hours, or an equal amount of PBS as a vehicle control. 
RNA was harvested using the RNeasy Midi Kit (Qiagen, 
Germantown, MD) according to manufacturer’s instructions, 
and resulting RNA was treated with RNase-Free DNase 
(Qiagen) to further remove any contaminating DNA from the 
samples. RNA was analyzed using a NanoDrop 1000 
Spectrophotometer to measure concentration and purity. 
Using the RT2 First Strand Kit (SABiosciences, Valencia, 
CA), cDNA was synthesized via reverse transcription from 1 
μg of purified RNA. Polymerase chain reaction (PCR) 
component mixes were prepared using RT2 SYBR Green 
Mastermix (SABiosciences) according to manufacturer’s 
instructions, and 25 μL mix was dispensed into each well of 
the RT2 Profiler PCR Human Tumor Metastasis Array 
(SABiosciences, PAHS-028ZD-2). The plates were run using 
the CFX96 Real-Time System cycler (BioRad, Hercules, 
CA), adhering to a two-step cycling program. One 10-minute 
cycle at 95°C was followed by 40 cycles of 95°C for 15 
seconds and 60°C for 1 minute. The ΔΔCt method for 
analysis was employed using the SABiosciences web portal 
located online at (www.SABiosciences.com/ 
pcrarray.dataanalysis.php). Accuracy and quality control 
across multiple plates was ensured by maintaining the same 
threshold value was used across all plates. The data were 
normalized across all plates to five housekeeping genes that 
included: beta actin (ACTB), beta-2-microglobulin (B2M), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
hypoxanthine phosphoribosyltransferase 1 (HPRT1), and 
ribosomal protein L13a (RPL13A). Standards for RNA 
quality, genomic DNA contamination, and PCR performance 
were all within the manufacturer’s recommended ranges. 
Data from three biological replicates for each array were 
used to calculate the fold change values from of the 
cmvIL-10 treated cells relative to PBS-treated control cells.   
Enzyme-Linked Immunosorbent Assay (ELISA). Clear 
bottom 96-well plates were seeded with 5x103 MCF-7 cells 
per well and treated with 0, 1, 10, or 100 ng/mL purified 
recombinant cmvIL-10 (R&D Systems) in triplicate. Cell 
supernatants were harvested at various time points for 
subsequent analysis. Cell lysates were also collected from 
these plates by adding 100μL cell lysis buffer (150mM NaCl, 
20 mM HEPES, 0.5% Triton X-100, 1mM NaOV4, 1mM 
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EDTA, 0.1% NaN3) with fresh protease inhibitor 
(Calbiochem, La Jolla, CA) onto the cells and administering 
a freeze-thaw cycle. MMP-10 protein levels were determined 
by sandwich ELISA according to manufacturer’s instructions 
(R&D Systems Duo Set DY910). Protein concentrations 
were determined by interpolation from a standard curve with 
an R2 value greater than 0.99 using the Opsys MR plate 
reader and Revelation Quicklink 4.24 software (Dynex 
Technologies, Chantilly, VA). 
Results and Discussion 
In order to investigate whether cmvIL-10 might have an 
effect on ER-positive tumors, we first examined MCF-7 breast 
cancer cells for the presence of the IL-10 receptor complex. 
Flow cytometry revealed that low levels of both the IL-10Rα 
and IL-10Rβ chains could be detected on the surface of 
MCF-7 cells (Fig. 1A). Immunofluorescence staining of 
permeabilized cells indicated that the IL-10Rα chain was 
present not only on the surface, but throughout the cytoplasm 
(Fig. 1B), which is consistent with reports that this receptor 
undergoes constitutive endocytosis in the absence of ligand 
binding [23]. 
Since both chains of the IL-10 receptor complex are present 
on and in MCF-7 cells, we examined whether exposure to 
cmvIL-10 might alter cell physiology. Cells were cultivated in 
the presence of varying doses of cmvIL-10 and cell growth 
monitored over time. As shown in Figure 1C, cmvIL-10 
caused a statistically significant increase in cell proliferation 
after 72 hours in culture. The effect of the viral cytokine was 
also dose-dependent, with the highest concentration (100 
ng/ml) causing the maximum level of cell growth.  These 
results indicate that cmvIL-10 has the ability to promote cell 
growth of already rapidly growing cancer cells. We have 
previously reported that cmvIL-10 stimulated growth of the 
MDA-MB-231 triple-negative breast cancer cell line [22], so 
these findings are consistent with those observations and 
support the notion that cmvIL-10 may enhance the invasive 
potential of breast cancer cells.   
Next we investigated whether cmvIL-10 would impact 
migration of MCF-7 cells. Cells were pre-treated with either 
100 ng/ml cmvIL-10 or PBS vehicle control for 24 hours, then 
harvested for a motility assay. Using a trans-well migration 
system, we quantified cells that traversed the filter and entered 
the lower chamber containing medium supplemented with 
FBS. As shown in Figure 1D, MCF-7 cells were highly motile 
and exhibited maximal chemotaxis toward 1% FBS. MCF7 
cells incubated in the presence of cmvIL-10 prior to and 
during the assay exhibited more motility than untreated cells.  
When cmvIL-10 was present in both chambers, the number of 
cells that crossed the filter into the lower chamber 
significantly increased, demonstrating that cmvIL-10 
effectively enhances cell movement. Tumor cells exhibiting 
an increased rate of proliferation and migration are more 
likely to leave the primary tumor site and travel to other parts 
of the body, so these findings indicate that cmvIL-10 might 
Figure 2. Tumor metastasis array gene expression. A) Functional 
clustering of genes involved in cell adhesion showing fold change of 
cmvIL-10 treated cells relative to untreated cells. B) Functional 
clustering of genes for MMPs and TIMPs showing fold change of 
cmvIL-10 treated cells relative to untreated cells. Error bars 
represent standard error from three biological replicates. C) MMP-10 
protein ELISA on supernatants and lysates from MCF-7 cells 
cultured in the presence or absence of cmvIL-10. Error bars 
represent standard error, * indicates p < 0.01, Student’s t test. These 
results are representative of three independent experiments. 
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have the potential to stimulate metastasis in vivo.  
A Human Tumor Metastasis PCR Array was used to 
examine specific cellular genes that were affected by 
cmvIL-10. RNA was extracted from MCF-7 cells cultivated in 
the presence or absence of cmvIL-10 for 24 hours, then cDNA 
prepared and applied to the array. Fold changes in gene 
expression were determined by comparing the untreated cells 
to those exposed to cmvIL-10. The most significant change 
was in expression of MCAM, or melanoma cell adhesion 
molecule, also known as CD146 and MUC18, which was 
up-regulated more than 8-fold compared to control cells (Fig. 
2A). High levels of MCAM in human breast cancer cells are 
associated with loss of cell-cell contacts, expression of 
markers related to a phenotypic epithelial to mesenchymal 
transition, and increased cell motility [24, 25]. Additionally, 
treatment with cmvIL-10 resulted in a 2.24-fold up-regulation 
of FXYD5, or FXYD domain containing ion transport 
regulator 5. Also known as dysadherin, FXYD5 is a gene 
involved in the reduction of cell adhesion via E-cadherin, as 
well as a biomarker for invasion [26]. Increased expression of 
these genes in tumor cells in response to cmvIL-10 would 
likely result in decreased attachment to the primary tumor 
mass.   
Treatment with cmvIL-10 also down-regulated genes 
associated with cell adhesion, particularly SYK, APC and 
CDH1. SYK, or spleen tyrosine kinase, is a tumor suppressor 
gene that inhibits tumor growth, invasion and metastasis in 
breast cancer cells [27]. APC, or adenomatous polyposis cell, 
is a tumor suppressor gene indicated in inhibiting tumor 
invasiveness [28]. Finally, the loss of function of CDH1, also 
known as cadherin 1 or E-cadherin, may contribute to tumor 
progression by increasing proliferation, invasion and 
metastasis [29]. The modulation of these cell adhesion genes 
demonstrates a shift in gene expression toward decreased 
attachment and an increased potential for movement away 
from the primary tumor.   
After MCAM, the most dramatic change in gene expression 
was a 4.8 fold increase in MMP-10 expression (Fig. 2B). 
MMPs degrade the extracellular matrix and permit tumor cells 
access to the vascular and lymphatic systems, allowing cancer 
dissemination. There was modest up-regulation of all MMPs 
genes analyzed in MCF-7 cells exposed to cmvIL-10 (1.32 – 
1.64 fold changes, as shown in Table 1). There was no 
remarkable change in TIMP (tissue inhibitor of 
metalloproteinases) gene expression to counteract the increase 
in MMP gene expression, with TIMP2, TIMP3, and TIMP4 
all exhibiting average fold-changes between 1 and 1.2 (Table 
1).  
To confirm that the changes in gene expression observed 
by qPCR array correlate with an increase in protein levels, 
supernatants and whole cell lysates from MCF-7 cells 
incubated in the presence or absence of cmvIL-10 were 
collected and analyzed for MMP-10 by ELISA. Although 
almost no MMP-10 was detected in supernatants, MMP-10 
was detected in lysates, which is not surprising since many 
MMPs remain attached to the membrane [30, 31]. MMP-10 
levels were significantly higher after 24-48 hours in the 
presence of 100 ng/ml cmvIL-10 (Fig. 2C). These results 
indicate that cmvIL-10 elevates production of MMP-10 
protein by cancer cells, which could be expected to enable 
access to the surrounding tissue and vasculature, ultimately 
promoting metastasis formation.   MMP-10 levels have been 
shown to be higher in breast cancer patients with lymph node 
metastases [32, 33], suggesting that these observations may 
correlate with events that occur during malignancy in vivo.   
In instances where HCMV-infected cells infiltrate the 
tumor microenvironment, the secretion of cmvIL-10 in may 
initiate events that promote a more invasive tumor phenotype. 
Cancer cells that replicate faster and express fewer adhesion 
molecules are more likely to dissociate from the primary 
tumor. In addition, MMPs degrade the extracellular matrix, 
promoting cancer cell dissemination by permitting tumor cells 
access to the vascular and lymphatic systems.  Our results 
show a possible role for cmvIL-10 in promoting malignancy 
and suggest that HCMV-positive cancer patients may benefit 
from the inclusion of anti-viral therapeutics in their treatment 
regimen.  
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